Chemotherapy before surgery for advanced rectal cancer
Treatments studied
Part of Cancer clinical trials.
This study tests whether giving a special form of chemotherapy (irinotecan liposomes) before surgery can help shrink rectal cancer tumors and improve outcomes. It is for people with locally advanced rectal cancer who have not yet had any treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with rectal cancer that has grown into or through the rectal wall, or has spread to nearby lymph nodes (based on MRI).
- The tumor is within 10 cm of the anal opening.
- You are generally able to do light activity (ECOG score 0 or 1).
- You have a specific gene type (UGT1A1) that is either normal or has one change – your doctor can check this with a blood test.
- You have not had any prior treatment for rectal cancer, such as surgery, chemotherapy, or radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a sequence of chemotherapy and radiation before and after surgery for rectal cancer. It compares giving more chemo between the end of radiation and surgery (consolidation) versus giving some chemo before radiation starts (induction). The goal is to see which order works better.
This trial tests a combination of drugs given before surgery to shrink rectal cancer tumors and improve the chances of successful surgery. The drugs include an immunotherapy called serplulimab, chemotherapy (XELOX), and a targeted therapy called bevacizumab. This approach may help reduce the risk of the cancer coming back.
This study tests a combination of chemotherapy, radiation, and an immunotherapy drug (called anti-PD-1) before surgery for rectal cancer that has not spread. The goal is to see if this approach can shrink or eliminate the tumor, potentially improving outcomes.
This trial tests a new combination of chemotherapy, radiation, and immunotherapy given before surgery for low rectal cancer. It aims to see if this approach can shrink tumors and improve outcomes for patients with a specific type of cancer that is microsatellite stable (MSS).
This trial tests giving a strong chemotherapy combination (FOLFIRINOX) followed by radiation before surgery for locally advanced rectal cancer. If you have stage 3 or high-risk stage 2 rectal cancer that has not spread, this approach may shrink the tumor and improve outcomes.
This trial compares different combinations of chemotherapy drugs given before surgery to the standard approach of chemoradiation (chemotherapy plus radiation) for rectal cancer that has not spread. The goal is to see if the drug combinations are more effective at shrinking tumors and improving outcomes.
Hear when a new Locally Advanced Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.